Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with CKD
Clinical Journal of the American Society of Nephrology · 2026-11 · 21 (11) · 1914-1927
DOI: 10.2215/cjn.0000001188 ↗Abstract
Key Points In this large cohort of US veterans with CKD, unlike niacin, long-term fibrate use (compared with statin use) was associated with slower eGFR decline. There was no statistically significant difference in the risk of major adverse kidney events in fibrate and niacin users compared with statin users. The potential renoprotective effects of fibrates can be particularly useful in patients with CKD who require triglyceride-lowering and HDL-elevating effects. Background Dyslipidemia, distinctly characterized by hypertriglyceridemia and impaired HDL cholesterol metabolism in patients with CKD, is associated with kidney disease progression. However, evidence on the renal outcomes of triglyceride-targeting lipid-lowering therapies, such as fibrates and niacin, often prescribed to patients with non–dialysis-dependent CKD, is insufficient and equivocal. Methods We designed this retrospective cohort study using a target trial emulation framework and leveraged data from a nationwide cohort of 3,562,882 US veterans to identify patients with incident CKD initiating de novo lipid-lowering therapies. We compared eGFR decline from baseline and the odds of rapid eGFR decline in fibrate and niacin initiators versus statin initiators using the mixed-effects model–predicted 1-, 3-, and 10-year eGFR slopes, adjusted for baseline covariates. We also compared the risk of major adverse kidney events (composite of a sustained ≥57% decrease in eGFR from baseline, sustained eGFR
EUVIMED